The Patent Finder

Synta Pharmaceuticals Corp.

21 patents currently held · Updated Nov 15, 2026
13 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 6 name spellings.

Recorded as renamed to Madrigal Pharmaceuticals, Inc. (2017)

17
Ending by 2030
May 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 30, 2026
    The maintenance fee for Pyrrole Compounds That Modulate HSP90 Activity (US 9,067,884) comes due Dec 30, 2026. Unpaid by Jun 30, 2027, it lapses early.
  • 1 fee due Jan 28, 2027
    The maintenance fee for Triazone Compounds That Modulate HSP90 Activity (US 9,090,569) comes due Jan 28, 2027. Unpaid by Jul 28, 2027, it lapses early.
  • 2 fees due Feb 11 to 18, 2027 · next Feb 11
  • 2 fees due Mar 1 to 8, 2027 · next Mar 1
  • 2 fees due Jun 8 to 10, 2027 · next Jun 8

Which patents, and when each one lapses · Pro

Recent changes

  • 3 terms have ended since Aug 17, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 8,183,384Triazole Compounds That Modulate HSP90 Activity
In force (reinstated)
 · High confidence
In force (reinstated)High confidence
US 8,927,548Triazole Compounds That Modulate HSP90 Activity
In force
 · Medium confidence
In forceMedium confidence
US 9,006,277Triazole Compounds That Modulate HSP90 Activity
In force
 · High confidence
In forceHigh confidence
US 9,206,162Triazole Compounds That Modulate HSP90 Activity
In force
 · High confidence
In forceHigh confidence
US 7,825,148Triazole Compounds That Modulate HSP90 Activity
In force
 · High confidence
In forceHigh confidence
US 8,063,083Method for Treating Non-Hodgkin's Lymphoma
In force
 · High confidence
In forceHigh confidence
US 9,108,933Method for Treating Proliferative Disorders Associated with Mutations in C-Met
In force
 · Medium confidence
In forceMedium confidence
US 9,120,745Triazole Compounds That Modulate HSP90 Activity
In force
 · Medium confidence
In forceMedium confidence
US 8,969,396Method for treating a B-raf associated cancer with an Hsp90 inhibitor
In force
 · Medium confidence
In forceMedium confidence
US 8,188,075Triazole Compounds That Modulate HSP90 Activity
In force
 · High confidence
In forceHigh confidence
10 of 21 patents shown.
Pro members see all 21.
Pro members: see all 21 patents
Also on record, not counted in the 21: 13 patents in force now held by others · 126 lapsed for an unpaid fee · 27 ended at full term · 1 past the fee grace period. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

3 abandoned · 101 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited